Kyasanur Forest Disease (KFD) is a neglected, tick‑borne viral haemorrhagic fever of the Western Ghats (India) that has expanded geographically since its first recognition in 1957 in Shimoga district, Karnataka. The KFD...
Summary This analysis provides a comprehensive estimate of the future global lives saved through vaccination, modeling the projected mortality benefits if all countries achieve high coverage for 14 key vaccine...
Summary This study evaluates the effectiveness of seasonal influenza vaccination in California by analyzing data from mandatory statewide public health reporting systems for influenza laboratory results and administered...
The Influenza vaccination After Myocardial Infarction (IAMI) trial is a pivotal, multicenter, randomized, double-blind, placebo-controlled study designed to assess the clinical benefit and safety of influenza...
Using an innovative study design, Fröbert et al. report that influenza vaccination within 72 hours of hospital admission for myocardial infarction significantly reduced all-cause and cardiovascular mortality over 12...
Several major global vaccine manufacturers released updates and company news since October 25, 2025, spanning Western, Asian, and African producers. Western Producers Dynavax Technologies (USA): Reported increased...
SummaryThis comprehensive systematic review by leading US researchers, published in the New England Journal of Medicine, synthesizes new evidence on the effectiveness and safety of COVID-19, RSV, and influenza vaccines...
The October 2025 issue of POLIO NEWS underscores the urgent global need for polio eradication and highlights how ongoing outbreaks, regional collaboration, and donor support remain pivotal to the effort. Key updates and...
The article presents an extensive global analysis of the introduction, establishment, and spread of non-native mosquito species implicated in human disease transmission, with direct implications for clinical...
Western Companies Moderna announced topline results from a Phase 3 pivotal trial evaluating mRNA-1647, an investigational cytomegalovirus (CMV) vaccine. The study did not meet its primary efficacy endpoint of preventing...